1. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
- Author
-
Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, and Williams M
- Subjects
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pharmacology, 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine pharmacology, Adamantane administration & dosage, Adamantane metabolism, Adamantane pharmacology, Administration, Oral, Animals, Antiparkinson Agents administration & dosage, Antiparkinson Agents metabolism, Benzazepines pharmacology, Benzopyrans administration & dosage, Benzopyrans metabolism, Binding Sites, Callithrix, Cell Line, Dopamine Agents administration & dosage, Dopamine Agents metabolism, Fishes, Injections, Subcutaneous, Mice, Motor Activity drug effects, Oxidopamine pharmacology, Parkinson Disease, Secondary chemically induced, Rats, Receptors, Dopamine D1 drug effects, Adamantane analogs & derivatives, Antiparkinson Agents pharmacology, Benzopyrans pharmacology, Dopamine Agents pharmacology, Parkinson Disease, Secondary drug therapy, Receptors, Dopamine D1 metabolism
- Abstract
A-77636, ((1R,3S) 3-(1'-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benz opyran hydrochloride), is a selective dopamine D1 receptor agonist. In a battery of receptor binding assays, A-77636 shows the highest affinity (pKi = 7.40 +/- 0.09; Ki = 39.8 nM) for the dopamine D1 receptor. A-77636 is an agonist at the dopamine D1 receptors in the fish retina (pEC50 = 8.13; EC50 = 1.1 nM; intrinsic activity = 102% of dopamine) and the rat caudate-putamen (pEC50 = 8.97; intrinsic activity = 134% of dopamine). The compound is functionally inactive at dopamine D2 receptors (EC50 > 10 microM). In rats with unilateral 6-OHDA (6-hydroxydopamine) lesions of the nigro-striatal dopaminergic pathway, A-77636 elicits prolonged (> 20 h) contralateral turning that is blocked by SCH 23390, a D1 receptor antagonist, but not by haloperidol at doses selective for the dopamine D2 receptor. Higher doses of A-77636 produce forelimb clonus in rats and mice. When tested in marmosets treated with MPTP to induce a parkinsonian-like state, A-77636 increases locomotor activity and decreases the severity of the parkinsonian-like symptoms: the compound is active after either subcutaneous or oral administration. A-77641, the optical antipode of A-77636, has a lower affinity towards the dopamine D1 receptor (pKi = 5.14, Ki = 7200 nM), is less potent as a dopamine D1 receptor agonist (pEC50 = 5.65; EC50 = 2200 nM), fails to elicit turning in the 6-OHDA-lesioned rat, and lacks antiparkinsonian efficacy in the MPTP-treated marmoset.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
- Full Text
- View/download PDF